Expression of the RNA-binding protein CRD-BP in brain and non-small cell lung tumors

被引：34

作者：

Ioannidis, P

Kottaridi, C

Dimitriadis, E

Courtis, N

Mahaira, L

Talieri, M

Giannopoulos, A

Iliadis, K

Papaioannou, D

Nasioulas, G

Trangas, T

机构：

[1] HYGEIA Antonis Papayiannis, Mol Biol Res Ctr, Athens 15123, Greece

[2] St Savas Hosp, Dept Genet, Athens, Greece

[3] St Savas Hosp, Oncol Res Ctr, Athens, Greece

[4] Univ Hosp Heraclion, Dept Neurosurg, Iraklion, Greece

[5] HYGEIA, Diagnost & Therapeut Ctr Athens, Thorac Surg Clin, Athens 15123, Greece

[6] HYGEIA, Diagnost & Therapeut Ctr Athens, Dept Anat Pathol, Athens 15123, Greece

来源：

CANCER LETTERS | 2004年 / 209卷 / 02期

关键词：

c-myc mRNA binding protein; coding region determinant-binding protein; non small cell lung cancer; brain tumors;

D O I：

10.1016/j.canlet.2003.12.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The coding region determinant-binding protein (CRD-BP) is an RNA binding protein that recognizes c-myc and IGF-II leader 3 mRNAs as well as the oncofetal H 19 RNA. CRD-BP exhibits an oncofetal pattern of expression and has been detected in the majority of colon (81%), breast (58.5%) and sarcoma (73%) tumors. The study of CRD-BP expression was extended in brain tumors and Non small cell lung (NSCL) carcinomas and 12/24 malignant, 215 benign neuroepithelial tumors and 4/15 of NSCL carcinomas were found positive. All normal matching tissues tested were found negative. The highest frequency (60%) of CRD-BP positive tumors was observed in meningiomas, either benign (11/18) or atypical (3/3). These findings confirm that CRD-BP expression is restricted in tumors; the frequency of its de novo expression may vary according to tumor type and appears to be an early event in the transformation process. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：245 / 250

页数：6

共 23 条

[1] CONTROL OF C-MYC MESSENGER-RNA HALF-LIFE INVITRO BY A PROTEIN CAPABLE OF BINDING TO A CODING REGION STABILITY DETERMINANT [J].